Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: primary day-28 analysis of a phase 2/3 open-label study

Katia Alves, Alex Kouassi, Joyce S. Plested, Raj Kalkeri, Katherine Smith, Muneer Kaba, Joy Nelson, Mingzhu Zhu, Shane Cloney-Clark, Zhaohui Cai, Raburn M. Mallory, Fernando Noriega the 2019nCoV-313 Study
doi: https://doi.org/10.1101/2024.10.25.24316129
Back to top
Posted November 01, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: primary day-28 analysis of a phase 2/3 open-label study
Katia Alves, Alex Kouassi, Joyce S. Plested, Raj Kalkeri, Katherine Smith, Muneer Kaba, Joy Nelson, Mingzhu Zhu, Shane Cloney-Clark, Zhaohui Cai, Raburn M. Mallory, Fernando Noriega
medRxiv 2024.10.25.24316129; doi: https://doi.org/10.1101/2024.10.25.24316129
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area